Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "bundlepackageleaflet-en-616a2493f2581291ddc019d50fec7c8b",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"
]
},
"language" : "en",
"identifier" : {
"system" : "http://ema.europa.eu/identifier",
"value" : "None"
},
"type" : "document",
"timestamp" : "2023-06-27T10:09:22Z",
"entry" : [
{
"fullUrl" : "Composition/composition-en-616a2493f2581291ddc019d50fec7c8b",
"resource" : {
"resourceType" : "Composition",
"id" : "composition-en-616a2493f2581291ddc019d50fec7c8b",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-616a2493f2581291ddc019d50fec7c8b\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-616a2493f2581291ddc019d50fec7c8b</b></p><a name=\"composition-en-616a2493f2581291ddc019d50fec7c8b\"> </a><a name=\"hccomposition-en-616a2493f2581291ddc019d50fec7c8b\"> </a><a name=\"composition-en-616a2493f2581291ddc019d50fec7c8b-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/14/947/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - xultophy</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/14/947/001"
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package Leaflet"
},
"category" : [
{
"coding" : [
{
"system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
"code" : "R",
"display" : "Raw"
}
]
}
],
"subject" : [
{
"reference" : "MedicinalProductDefinition/mp616a2493f2581291ddc019d50fec7c8b"
}
],
"date" : "2022-02-16T13:28:17Z",
"author" : [
{
🔗 "reference" : "Organization/mah-ema"
}
],
"title" : "TEST PURPOSES ONLY - xultophy",
"attester" : [
{
"mode" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/composition-attestation-mode",
"code" : "official"
}
]
},
"time" : "2022-02-16T13:28:17Z"
}
],
"section" : [
{
"title" : "B. Package Leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "B. Package Leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable"
}
]
},
"section" : [
{
"title" : "Package leaflet: Information for the user",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package leaflet: Information for the user"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
}
},
{
"title" : "What is in this leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "What is in this leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What Xultophy is and what it is used for</li><li>What you need to know before you use Xultophy</li><li>How to use Xultophy</li><li>Possible side effects</li><li>How to store Xultophy</li><li>Contents of the pack and other information</li></ol></div>"
}
},
{
"title" : "1. What xultophy is and what it is used for",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "1. What xultophy is and what it is used for"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Xultophy is used for Xultophy is used to improve blood glucose (sugar) levels in adult patients with type 2 diabetes mellitus. You have diabetes because your body:</p><ul><li>does not make enough insulin to control the level of sugar in your blood or</li><li>is not able to use the insulin properly.</li></ul><p>How Xultophy works<br/>Xultophy contains two active substances that help your body control your blood sugar:</p><ul><li>insulin degludec a long-acting basal insulin which lowers your blood sugar levels.</li><li>liraglutide a GLP-1 analogue that helps your body make more insulin during meals and lowers the amount of sugar made by your body.</li></ul><p>Xultophy and oral medicines for diabetes Xultophy is used with oral medicines for diabetes (such as metformin, pioglitazone and sulfonylurea medicines). It is prescribed when these medicines (used alone or with GLP-1 treatment or with basal insulin) are not enough to control your blood sugar levels.</p><p>If you use GLP-1 treatment You should stop your GLP-1 treatment prior to starting on Xultophy.</p><p>If you use insulin You should stop your insulin treatment prior to starting on Xultophy.</p></div>"
}
},
{
"title" : "2. What you need to know before you take xultophy",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "2. What you need to know before you take xultophy"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Do not use Xultophy</p><ul><li>if you are allergic to insulin degludec or liraglutide or any of the other ingredients of this medicine (listed in section 6).</li></ul><p>Warnings and precautions<br/>Talk to your doctor, pharmacist or nurse before using Xultophy.</p><ul><li>If you are also taking a sulfonylurea (such as glimepiride or glibenclamide), your doctor may tell you to lower your sulfonylurea dose depending on your blood sugar levels.</li><li>Do not use Xultophy if you have type 1 diabetes mellitus or if you have ketoacidosis (a condition with a build-up of acid in the blood).</li><li>The use of Xultophy is not recommended in patients with inflammatory bowel disease or delayed gastric emptying (diabetic gastroparesis).</li></ul><p>Be especially aware of the following when using Xultophy:</p><ul><li>low blood sugar (hypoglycaemia) if your blood sugar is low, follow the advice in section 4 Low blood sugar (hypoglycaemia) .</li><li>high blood sugar (hyperglycaemia) if your blood sugar is high, follow the advice in section 4 High blood sugar (hyperglycaemia) .</li><li>Ensuring you use the right medicine Always check the pen label before each injection to avoid accidentally confusing Xultophy with other products.</li></ul><p>Important things to know before you use this medicine: Tell your doctor if you:</p><ul><li>have eye problems. Fast improvements in blood sugar control may make diabetic eye problems get worse for a short time. The long-term improvements in blood sugar control may ease the eye problems.</li><li>have or have had a thyroid disease.</li></ul><p>Important things to know while you are using this medicine:</p><ul><li>if you have a severe stomach ache which does not go away, tell your doctor this could be a sign of inflamed pancreas (acute pancreatitis).</li><li>dehydration (loss of fluids from the body) can happen if you are feeling or being sick (nausea or vomiting) or have diarrhoea it is important to drink plenty of fluids to stop dehydration.</li></ul><p>Skin changes at the injection site The injection site should be rotated to help prevent changes to the fatty tissue under the skin, such as skin thickening, skin shrinking or lumps under the skin. The insulin may not work very well if you inject into a lumpy, shrunken or thickened area (see section 3 How to use Xultophy ). Tell your doctor if you notice any skin changes at the injection site. Tell your doctor if you are currently injecting into these affected areas before you start injecting in a different area. Your doctor may tell you to check your blood sugar more closely, and to adjust your insulin or your other antidiabetic medications dose.</p><p>Children and adolescents Do not give this medicine to children or adolescents. There is no experience with Xultophy in children and adolescents under 18 years old.</p><p>Other medicines and Xultophy Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. Some medicines affect your blood sugar level this may mean your Xultophy dose has to change.</p><p>Listed below are the most common medicines, which may affect your Xultophy treatment.</p><p>Your blood sugar level may fall if you take:</p><ul><li>other medicines for diabetes (tablets or injections)</li><li>sulfonamides for infections</li><li>anabolic steroids such as testosterone</li><li>beta-blockers for high blood pressure. They may make it harder to recognise the warning signs of low blood sugar (see section 4 Warning signs of low blood sugar these may come on suddenly )</li><li>acetylsalicylic acid (and medicines called salicylates ) for pain and mild fever</li><li>monoamine oxidase (MAO) inhibitors for depression</li><li>angiotensin converting enzyme (ACE) inhibitors for some heart problems or high blood pressure.</li></ul><p>Your blood sugar level may rise if you take:</p><ul><li>danazol medicine affecting ovulation</li><li>oral contraceptives birth control pills</li><li>thyroid hormones for thyroid disease</li><li>growth hormone for low levels of growth hormone</li><li>medicines called glucocorticoids such as cortisone for inflammation</li><li>medicines called sympathomimetics such as epinephrine (adrenaline), salbutamol or terbutaline for asthma</li><li>water tablets called thiazides for high blood pressure or if your body is holding onto too much water (water retention).</li></ul><p>Octreotide and lanreotide used for treatment of acromegaly (a rare illness with too much growth hormone). They may increase or decrease your blood sugar level.</p><p>Pioglitazone tablets used for the treatment of type 2 diabetes mellitus. Some patients with long- standing type 2 diabetes mellitus and heart disease or previous stroke, who were treated with pioglitazone and insulin, experienced the development of heart failure. Inform your doctor straight away if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema).</p><p>Warfarin or other blood thinners medicines used to prevent clotting of the blood. Tell your doctor if you are taking warfarin or other blood thinners as you might need to have blood tests more often to measure how thick your blood is (called International Normalised Ratio or INR test).</p><p>Xultophy with alcohol If you drink alcohol, your need for Xultophy may change. Your blood sugar level may either rise or fall. You should therefore monitor your blood sugar level more often than usual.</p><p>Pregnancy and breast-feeding<br/>Do not use Xultophy if you are pregnant or plan to become pregnant. Tell your doctor if you are pregnant, think you might be pregnant or are planning to have a baby. It is not known if Xultophy affects the baby.</p><p>Do not use Xultophy if you are breast-feeding. It is not known if Xultophy passes into breast milk.</p><p>Driving and using machines<br/>Having low or high blood sugar can affect your ability to drive or use any tools or machines. If your blood sugar is low or high, your ability to concentrate or react might be affected. This could be dangerous to yourself or others. Ask your doctor whether you can drive if:</p><ul><li>you often get low blood sugar</li><li>you find it hard to recognise low blood sugar.</li></ul><p>Important information about some of the ingredients of Xultophy<br/>Xultophy contains less than 1 mmol sodium (23 mg) per dose. This means that the medicine is essentially sodium-free .</p></div>"
}
},
{
"title" : "3. How to take xultophy",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "3. How to take xultophy"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Always use this medicine exactly as your doctor has told you. Check with your doctor, pharmacist or nurse if you are not sure.</p><p>If you are blind or have poor eyesight and cannot read the dose counter on the pen, do not use this pen without help. Get help from a person with good eyesight who is trained to use the Xultophy pre-filled pen.</p><p>Your doctor will tell you:</p><ul><li>how much Xultophy you will need each day</li><li>when to check your blood sugar level</li><li>how to adjust the dose.</li></ul><p>Your dose of Xultophy is administered as dose steps . The dose counter on the pen shows the number of dose steps.</p><p>Dosing time</p><ul><li>Use Xultophy once each day, preferably at the same time every day. Choose a time of the day that works best for you.</li><li>If it is not possible to use Xultophy at the same time every day, it can be used at a different time of the day. Make sure to have a minimum of 8 hours between the doses.</li><li>You do not have to use Xultophy with a meal.</li><li>Always follow your doctor s advice for dose and dose adjustment.</li><li>If you want to change your usual diet, check with your doctor, pharmacist or nurse first as a change in diet may alter your need for Xultophy.</li></ul><p>How to handle Xultophy<br/>Xultophy is a pre-filled dial-a-dose pen.</p><ul><li>Xultophy is administered as dose steps . The dose counter on the pen shows the number of dose steps.</li><li>One dose step contains 1 unit of insulin degludec and 0.036 mg of liraglutide.</li><li>The maximum daily dose of Xultophy is 50 dose steps (50 units of insulin degludec and 1.8 mg of liraglutide). Carefully read the Instructions on how to use on the other side of this leaflet and use the pen as described.<br/>Always check the pen label before you inject your medicine to ensure that you use the correct pen.</li></ul><p>How to inject Before you use Xultophy for the first time, your doctor or nurse will show you how to inject.</p><ul><li>Xultophy is given as an injection under the skin (subcutaneously). Do not inject it into a vein or muscle.</li><li>The best places to inject are the front of your thighs, upper arms or the front of your waist (abdomen).</li><li>Change the place within the area where you inject each day to reduce the risk of developing lumps and skin pitting (see section 4).</li><li>Always use a new needle for each injection. Re-use of needles may increase the risk of blocked needles leading to inaccurate dosing. Dispose of the needle safely after each use.</li><li>Do not use a syringe to remove the solution from the pen to avoid dosing errors and potential overdose.</li></ul><p>Detailed instructions for use are on the other side of this leaflet.</p><p>Do not use Xultophy:</p><ul><li>If the pen is damaged or has not been stored correctly (see section 5).</li><li>If the liquid you can see through the pen window does not look clear and colourless.</li></ul><p>Use in elderly patients (65 years old or over) Xultophy can be used in elderly patients but if you are elderly you may need to check your blood sugar level more often. Talk to your doctor about changes in your dose.</p><p>If you have kidney or liver problems If you have kidney or liver problems, you may need to check your blood sugar level more often. Talk to your doctor about changes in your dose.</p><p>If you use more Xultophy than you should<br/>If you use more Xultophy than you should, your blood sugar may get low (hypoglycaemia) or you may feel or be sick (nausea or vomiting). If your blood sugar gets low, see the advice in section 4 Low blood sugar (hypoglycaemia) .</p><p>If you forget to use Xultophy<br/>If you forget a dose, inject the missed dose when discovering the mistake, ensuring a minimum of 8 hours between doses. If you discover that you missed your previous dose when it is time to take your next regular scheduled dose, do not take a double dose.</p><p>If you stop using Xultophy<br/>Do not stop using Xultophy without talking to your doctor. If you stop using Xultophy this could lead to a very high blood sugar level, see the advice in section 4 High blood sugar (hyperglycaemia) .</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p></div>"
}
},
{
"title" : "4. Possible side effects",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "4. Possible side effects"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following serious side effects may happen with this medicine:</p><ul><li>Low blood sugar (very common: may affect more than 1 in 10 people).<br/>If your blood sugar level gets low you may pass out (become unconscious). Serious hypoglycaemia may cause brain damage and may be life-threatening. If you have signs of low blood sugar, take actions to increase your blood sugar level straight away. See advice in Low blood sugar (hypoglycaemia) further down in this section.</li><li>Serious allergic reaction (anaphylactic reaction) (not known: frequency cannot be estimated from the available data).</li></ul><p>If you have a serious allergic reaction to any of the ingredients in Xultophy, stop using Xultophy and see a doctor straight away. The signs of a serious allergic reaction are:</p><ul><li><p>local reactions spread to other parts of your body</p></li><li><p>you suddenly feel unwell with sweating</p></li><li><p>you have difficulty breathing</p></li><li><p>you get a fast heartbeat or feel dizzy.</p></li></ul><p>Skin changes at the injection site: If you inject insulin at the same place, the fatty tissue may shrink (lipoatrophy) or thicken (lipohypertrophy) (may affect up to 1 in 100 people). Lumps under the skin may also be caused by build-up of a protein called amyloid (cutaneous amyloidosis; how often this occurs is not known). The insulin may not work very well if you inject into a lumpy, shrunken or thickened area. Change the injection site with each injection to help prevent these skin changes.</p><p>Other side effects include: Common (may affect up to 1 in 10 people)</p><ul><li>Lower appetite, feeling or being sick (nausea or vomiting), diarrhoea, constipation, indigestion (dyspepsia), inflamed lining of the stomach (gastritis), stomach ache, heartburn or bloating<br/>these usually go away after a few days or weeks.</li><li>Injection site reactions. The signs may include bruising, bleeding, pain, redness, hives, swelling or itching these usually go away after a few days. See your doctor if they do not disappear after a few weeks. Stop using Xultophy and see a doctor straight away if they become serious.</li><li>Increase of pancreatic enzymes, such as lipase and amylase.</li></ul><p>Uncommon (may affect up to 1 in 100 people)</p><ul><li>Hives (red bumps on your skin that are sometimes itchy).</li><li>Allergic reactions (hypersensitivity) such as rash, itching and swelling of the face.</li><li>Dehydration (loss of fluid from the body) it is important to drink plenty of fluids to stop dehydration.</li><li>Belching (eructation) and wind (flatulence).</li><li>Rash.</li><li>Itching.</li><li>Increased heart rate.</li><li>Gallstones.</li><li>Inflamed gallbladder.</li><li>Change in how things taste.</li></ul><p>Not known (frequency cannot be estimated from the available data)</p><ul><li>Inflamed pancreas (pancreatitis).</li><li>Swelling of arms or legs (peripheral oedema) when you first start using your medicine, your body may keep more water than it should. This causes swelling around your ankles and other joints. This is usually only short-lasting.</li></ul><p>General effects from diabetes treatment</p><p>Low blood sugar (hypoglycaemia)</p><p>Low blood sugar may happen if you:</p><ul><li>drink alcohol</li><li>exercise more than usual</li><li>eat too little or miss a meal</li><li>use too much Xultophy.</li></ul><p>Warning signs of low blood sugar these may come on suddenly Headache, slurred speech, fast heartbeat, cold sweat, cool pale skin, feeling sick (nausea), feeling very hungry, shaking, feeling nervous or worried, unusually tired, weak and sleepy or confused, difficulty concentrating, short-lasting changes in your sight.</p><p>What to do if you get low blood sugar:</p><ul><li>Eat glucose tablets or another high sugar snack like sweets, biscuits or fruit juice (always carry glucose tablets or a high sugar snack, just in case).</li><li>Measure your blood sugar if possible and rest. You may need to measure your blood sugar more than once. This is because improvement in your blood sugar may not happen straight away.</li><li>Wait until the signs of low blood sugar have gone or when your blood sugar level has settled. Then carry on with your medicine as usual.</li></ul><p>What others need to do if you pass out:<br/>Tell everyone you spend time with that you have diabetes. Tell them what could happen if your blood sugar gets low, including the risk of passing out.</p><p>Let them know that if you pass out, they must:</p><ul><li>turn you on your side</li><li>get medical help straight away</li><li>not give you any food or drink because you may choke.</li></ul><p>You may recover more quickly from passing out if you receive glucagon. This can only be given by someone who knows how to use it.</p><ul><li>If you are given glucagon, you will need sugar or a sugary snack as soon as you come round.</li><li>If you do not respond to glucagon treatment, you will have to be treated in a hospital.</li><li>If severe low blood sugar is not treated over time, it can cause brain damage. This can be short- or long-lasting. It may even cause death. Talk to your doctor if:</li><li>your blood sugar got so low that you passed out</li><li>you have used glucagon</li><li>you have had low blood sugar a few times recently. This is because the dosing of your Xultophy injections, food or exercise may need to be changed.</li></ul><p>High blood sugar (hyperglycaemia)</p><p>High blood sugar may happen if you:</p><ul><li>drink alcohol</li><li>exercise less than usual</li><li>eat more than usual</li><li>get an infection or a fever</li><li>have not used enough Xultophy, keep using less Xultophy than you need, forget to use Xultophy or stop using Xultophy without talking to your doctor.</li></ul><p>Warning signs of high blood sugar these normally appear gradually Flushed, dry skin, feeling sleepy or tired, dry mouth, fruity (acetone) breath, urinating more often, feeling thirsty, losing your appetite, feeling or being sick (nausea or vomiting). These may be signs of a very serious condition called ketoacidosis . This is a build-up of acid in the blood because the body is breaking down fat instead of sugar. If not treated, this could lead to diabetic coma and eventually death.</p><p>What to do if you get high blood sugar:</p><ul><li>Test your blood sugar level.</li><li>Test your blood or urine for ketones.</li><li>Get medical help straight away.</li></ul><p>Reporting of side effects<br/>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>"
}
},
{
"title" : "5. How to store xultophy",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "5. How to store xultophy"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the pen label and carton after EXP . The expiry date refers to the last day of that month.</p><p>Before opening Store in a refrigerator (2 C to 8 C). Keep away from the freezing element. Do not freeze.</p><p>During use Do not freeze. You can carry Xultophy with you and keep it at room temperature (no more than 30 C) or in a refrigerator (2 C to 8 C) for up to 21 days. The product should be thrown away 21 days after first opening.</p><p>Always keep the cap on the pre-filled pen when you are not using it in order to protect it from light.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>"
}
},
{
"title" : "6. Contents of the pack and other information",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "6. Contents of the pack and other information"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Xultophy contains</p><ul><li>The active substances are insulin degludec and liraglutide. Each mL of solution contains 100 units of insulin degludec and 3.6 mg liraglutide. Each unused pre-filled pen (3 mL) contains 300 units of insulin degludec and 10.8 mg liraglutide.</li><li>The other ingredients are glycerol, phenol, zinc acetate, hydrochloric acid and sodium hydroxide (for pH adjustment), and water for injections. See also section 2 Important information about some of the ingredients of Xultophy for information on sodium.</li></ul><p>What Xultophy looks like and contents of the pack Xultophy is a clear and colourless solution. Pack sizes of 1, 3, 5 and a multipack containing 10 (2 packs of 5) pens of 3 mL. Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder and Manufacturer Novo Nordisk A/S Novo All<br/>DK-2880 Bagsv rd, Denmark</p><p>Now turn over for information on how to use your pre-filled pen.</p><p>This leaflet was last revised in</p><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>"
}
}
]
}
]
}
},
{
"fullUrl" : "MedicinalProductDefinition/mp616a2493f2581291ddc019d50fec7c8b",
"resource" : {
"resourceType" : "MedicinalProductDefinition",
"id" : "mp616a2493f2581291ddc019d50fec7c8b",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mp616a2493f2581291ddc019d50fec7c8b\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mp616a2493f2581291ddc019d50fec7c8b</b></p><a name=\"mp616a2493f2581291ddc019d50fec7c8b\"> </a><a name=\"hcmp616a2493f2581291ddc019d50fec7c8b\"> </a><a name=\"mp616a2493f2581291ddc019d50fec7c8b-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/14/947/001</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Xultophy 100 units/mL + 3.6 mg/mL solution for injection.</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/14/947/001"
}
],
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-type",
"code" : "MedicinalProduct",
"display" : "Medicinal Product"
}
]
},
"domain" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-domain",
"code" : "Human",
"display" : "Human use"
}
]
},
"status" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/publication-status",
"code" : "active",
"display" : "active"
}
]
},
"legalStatusOfSupply" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi",
"code" : "100000072084",
"display" : "Medicinal product subject to medical prescription"
}
]
},
"name" : [
{
"productName" : "Xultophy 100 units/mL + 3.6 mg/mL solution for injection.",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000001",
"display" : "Full name"
}
]
},
"part" : [
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000002",
"display" : "Invented name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000003",
"display" : "Scientific name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000004",
"display" : "Strength part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000005",
"display" : "Pharmaceutical dose form part"
}
]
}
}
],
"usage" : [
{
"country" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"jurisdiction" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "en"
}
]
}
}
]
}
]
}
}
]
}
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
